Biohaven is betting hundreds of millions it can hustle ahead of rivals in a blockbuster race. A quick M&A deal could pay off backers big time
Biohaven $BHVN may not have anything like the market caps of its rivals at Allergan $AGN and Eli Lilly $LLY, but they’re not letting the David vs. Goliath status of their competition stop them from making a big bet on a fast win for a new oral drug to treat acute migraine. And they’re backed by a group that has an eye on a potential buyout.
The biotech has acquired a priority review voucher from GW Research for $105 million, looking to shave 4 months off their marketing application for rimegepant — a year after they managed to disenchant its investors with their positive Phase III data, which failed to dramatically break away from the placebo group.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.